TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.
- 2017 - 2022
Within this project we are acting as a service provider for metabolomics studies, involving vaccine candidates.
The BioMedical Metabolomics Facility Leiden (BMFL) offers a highly structured environment for advanced metabolomics studies. BMFL builds on fully validated, state-of-the-art platforms that each cover a part of the human metabolism and together span the complete human metabolome. In vitro and in vivo metabolomics is a powerful approach to characterise/evaluate the metabolic responses and changes occurring during immunisation and challenge studies.
Modality of access under this proposal: Users will provide samples and together we will decide the relevant metabolic pathways to target and profile, based on the applicant’s biological question(s). Data analysis of metabolic profiles can be carried out by the users, or supported by the facility. Users can be trained at the facility if needed. Support offered under this TNA: Comprehensive targeted metabolomics profiling based on liquid chromatography – mass spectrometry. Platforms included: Lipid metabolism, Bile acids, Organic acids Central Carbon metabolism, Biogenic amines and amino acids, Acyl-carnitines, Eicosanoids, Endocannabinoids and oxidative stress markers. In agreement with the facility, users will decide the scope of the service, including which platforms are to be used. Samples matrixes suitable for metabolomics analyses include in vitro: cell lysate and medium, and in vivo: Plasma, serum, urine, CSF, micro-dialysate and tissues.